Publications by authors named "Ciric To"

Claim this Profile
M
Molecular Bidents with Two Electrophilic Warheads as a New Pharmacological Modality.
Zhengnian Li, Jie Jiang, Scott B Ficarro, Tyler S Beyett, Ciric To, Jarrod A Marto

ACS Cent Sci· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Constitutive EGFR Kinase Dimer to Study Inhibitor Pharmacology.
Justin J Kim, Ilse K Schaeffner, David E Heppner, Ciric To, Pasi A Jänne

Mol Pharmacol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC.
Thomas W Gero, David E Heppner, Tyler S Beyett, Ciric To, Seth C Azevedo

Bioorg Med Chem Lett· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors.
Tyler S Beyett, Ciric To, David E Heppner, Jaimin K Rana, Anna M Schmoker

Nat Commun· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.
Ciric To, Tyler S Beyett, Jaebong Jang, William W Feng, Magda Bahcall

Nat Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites.
Florian Wittlinger, David E Heppner, Ciric To, Marcel Günther, Bo Hee Shin

J Med Chem· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of -mutant lung cancer.
Pınar Özden Eser, Raymond M Paranal, Jieun Son, Elena Ivanova, Yanan Kuang, Ciric To

Sci Transl Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations.
Jaebong Jang, Ciric To, Dries J H De Clercq, Eunyoung Park, Charles M Ponthier

Angew Chem Int Ed Engl· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.
Kari J Kurppa, Yao Liu, Ciric To, Tinghu Zhang, Mengyang Fan, Jarrod A Marto

Cancer Cell· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
Deepa Rangachari, Ciric To, Jason E Shpilsky, Paul A VanderLaan, Susumu S Kobayashi

J Thorac Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors.
Dries J H De Clercq, David E Heppner, Ciric To, Jaebong Jang, Eunyoung Park

ACS Med Chem Lett· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor.
Ciric To, Jaebong Jang, Ting Chen, Eunyoung Park, Mierzhati Mushajiang

Cancer Discov· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a potent dual ALK and EGFR T790M inhibitor.
Jaebong Jang, Jung Beom Son, Ciric To, Magda Bahcall, So Young Kim

Eur J Med Chem· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic triterpenoids inhibit GSK3β activity and localization and affect focal adhesions and cell migration.
Ciric To, Ashbeel Roy, Eddie Chan, Marco A M Prado, Gianni M Di Guglielmo

Biochim Biophys Acta Mol Cell Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis.
Ciric To, Carol S Ringelberg, Darlene B Royce, Charlotte R Williams, Renee Risingsong

Carcinogenesis· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP inhibitors for chemoprevention--reply.
Ciric To, Michael B Sporn, Karen T Liby

Cancer Prev Res (Phila)· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.
Ciric To, Eun-Hee Kim, Darlene B Royce, Charlotte R Williams, Ryan M Collins

Cancer Prev Res (Phila)· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic triterpenoids target the Arp2/3 complex and inhibit branched actin polymerization.
Ciric To, Brian H Shilton, Gianni M Di Guglielmo

J Biol Chem· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid-imidazolide alters transforming growth factor beta-dependent signaling and cell migration by affecting the cytoskeleton and the polarity complex.
Ciric To, Sarang Kulkarni, Tony Pawson, Tadashi Honda, Gordon W Gribble

J Biol Chem· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis